论文部分内容阅读
背景:胃癌的生长和转移与新生血管的生成密切相关。血管内皮生长因子(VEGF)鄄A在肿瘤组织中大量表达,在肿瘤血管生成中发挥重要作用。目的:测定胃癌患者循环血液中VEGF鄄A的含量,并探讨其临床意义。方法:选取经内镜和病理检查证实的135例胃癌患者和48例胃良性疾病患者,采用酶联免疫吸附测定(ELISA)方法测定其血浆和血清VEGF鄄A含量。10例手术前胃癌患者和10例胃良性疾病患者于1周后、16例胃癌患者于术后3周再次测定血清VEGF鄄A含量。结果:135例胃癌患者的血浆和血清VEGF鄄A含量显著高于48例胃良性疾病患者(血浆:74.1pg/ml±96.0pg/ml对23.7pg/ml±16.9pg/ml,P<0.001;血清:342.1pg/ml±277.8pg/ml对80.0pg/ml±36.4pg/ml,P<0.0001)。10例手术前胃癌患者1周前后的血清VEGF鄄A含量分别为264.3pg/ml±148.2pg/ml和265.2pg/ml±142.9pg/ml,10例胃良性疾病患者分别为71.4pg/ml±16.2pg/ml和78.0pg/ml±14.3pg/ml,差异均无显著性(P>0.05)。16例胃癌患者术前和术后3周的血清VEGF鄄A含量分别为328.4pg/ml±141.7pg/ml和103.5pg/ml±52.2pg/ml,差异有显著性(P<0.0001)。结论:胃癌患者的血浆和血清VEGF鄄A含量显著增高,血清VEGF鄄A含量较稳定。胃癌切除术后血清VEGF鄄A含量显著降低。
Background: The growth and metastasis of gastric cancer are closely related to the formation of neovascularization. Vascular endothelial growth factor (VEGF) -A is highly expressed in tumor tissues and plays an important role in tumor angiogenesis. Objective: To determine the content of VEGF-A in circulating blood of patients with gastric cancer and to explore its clinical significance. Methods: 135 patients with gastric cancer and 48 patients with benign gastric diseases confirmed by endoscopy and pathology were enrolled in this study. The plasma and serum VEGF-A levels were determined by enzyme linked immunosorbent assay (ELISA). After one week in 10 patients with preoperative gastric cancer and 10 patients with gastric benign disease, serum VEGF-A levels were measured again in 16 patients with gastric cancer at 3 weeks after operation. Results: Plasma and serum VEGF-A levels were significantly higher in 135 patients with gastric cancer than in 48 patients with gastric benign disease (plasma: 74.1 pg / ml ± 96.0 pg / ml versus 23.7 pg / ml ± 16.9 pg / ml, P <0.001; Serum: 342.1 pg / ml ± 277.8 pg / ml vs 80.0 pg / ml ± 36.4 pg / ml, P <0.0001). The serum levels of VEGF-A in the 10 patients with preoperative gastric cancer were 264.3 pg / ml ± 148.2 pg / ml and 265.2 pg / ml ± 142.9 pg / ml, respectively, and 10 patients with gastric benign disease were 71.4 pg / ml ± 16.2pg / ml and 78.0pg / ml ± 14.3pg / ml, no significant difference (P> 0.05). The serum levels of VEGF-A in patients with gastric cancer before and after 3 weeks were 328.4pg / ml ± 141.7pg / ml and 103.5pg / ml ± 52.2pg / ml, respectively, with significant difference (P <0.0001). Conclusion: The content of VEGF-A in plasma and serum of patients with gastric cancer is significantly higher, and the content of serum VEGF-A is more stable. After gastric cancer resection, serum VEGF-A content was significantly lower.